Gan & Lee Pharmaceuticals (603087.SH) announced that it has recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for its investigational drug, GLR1075 Injection.

Upon review, the clinical trial application for GLR1075 Injection, accepted on July 3, 2026, complies with the relevant requirements for drug registration, and the company has been granted permission to conduct clinical trials for cirrhotic ascites with hypoalbuminemia.

GLR1075 Injection is a recombinant human albumin preparation independently developed by Gan & Lee Pharmaceuticals, categorized as a humanized recombinant protein drug. Its active ingredient, recombinant human albumin, shares the same amino acid sequence and a similar spatial conformation as natural human serum albumin, enabling it to perform albumin's core physiological functions, including correcting colloid osmotic pressure imbalances and improving the pathological microenvironment.